The Clinical Significance of Molecular Markers to Bladder Cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Hybridoma and Hybridomics

• Publication date

  2004-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hyb.2004.23.335PMID 15684659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma

  2004cited by this paper
• Clinical significance of heat shock protein-70 expression in bladder cancer.

  2003cited by this paper
• Telomerase: Its clinical relevance in the diagnosis of bladder cancer

  2002cited by this paper
• Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer.

  2002cited by this paper
• Biomarkers for the Detection of Bladder Cancer

  2001cited by this paper
• Urine detection of survivin and diagnosis of bladder cancer.

  2001cited by this paper
• HEAT SHOCK RESPONSE AND AGEING: MECHANISMS AND APPLICATIONS

  2001cited by this paper
• Molecular markers for diagnosis, staging, and prognosis of bladder cancer.

  2001cited by this paper
• The Role of E-Cadherin-Catenin Complex: More Than an Intercellular Glue?

  2000cited by this paper
• Urinary markers of malignancy.

  2000cited by this paper
• p53 Expression Predicts Progression and Poor Survival in T1 Bladder Tumours

  2000cited by this paper
• The Role of E-Cadherin-Catenin Complex: More Than an Intercellular Glue?

  2000cited by this paper
• Epithelial mucin expression in bladder cancer: correlation with pathological and clinical parameters

  2000cited by this paper
• Expression patterns of the E-cadherin-catenin cell-cell adhesion complex in gastric cancer.

  2000cited by this paper
• The role of E-cadherin-catenin complex: more than an intercellular glue?

  2000cited by this paper
• Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas

  2000cited by this paper
• Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.

  2000cited by this paper
• The genetics of transitional cell carcinoma: progress and potential clinical application

  1999cited by this paper
• Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers.

  1999cited by this paper
• Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors.

  1999cited by this paper
• Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.

  1999cited by this paper
• Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer

  1999cited by this paper
• Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence.

  1999cited by this paper
• Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma.

  1999cited by this paper
• Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.

  1999cited by this paper
• Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine.

  1999cited by this paper
• Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31

  1999cited by this paper
• Role of adhesion molecules in bladder cancer: an important part of the jigsaw.

  1999cited by this paper
• Prognostic Value of MIB-1 Score, p53, EGFr, Mitotic Index and Papillary Status in Primary Superficial (Stage pTa/T1) Bladder Cancer: A Prospective Comparative Study

  1999cited by this paper
• Expression and Tissue Localization of Membrane-Types 1,2,and 3 Matrix Metalloproteinases in Human Urothelial Carcinomas

  1999cited by this paper
• Bladder cancer : biology, diagnosis, and management

  1999cited by this paper
• Abnormal expression of p120 correlates with poor survival in patients with bladder cancer.

  1998cited by this paper
• Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.

  1998cited by this paper
• Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer.

  1998cited by this paper
• Prognostic markers in bladder cancer: a contemporary review of the literature.

  1998cited by this paper
• Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas.

  1998cited by this paper
• Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer.

  1998cited by this paper
• In vitro cytotoxicity following specific activation of amygdalin by β‐glucosidase conjugated to a bladder cancer‐associated monoclonal antibody

  1998cited by this paper
• Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer.

  1998cited by this paper
• Markers in bladder cancer--issues to consider.

  1998cited by this paper
• Molecular mediators of angiogenesis in bladder cancer.

  1998cited by this paper
• Prospects for optimized clinical management of bladder cancer by application of phenotypic markers.

  1998cited by this paper
• Non‐radioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine

  1998cited by this paper
• Telomerase Catalytic Subunit Homologs from Fission Yeast and Human

  1997cited by this paper
• Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.

  1997cited by this paper
• The prognostic value of p53 nuclear overexpression and MIB‐1 as a proliferative marker in transitional cell carcinoma of the bladder

  1997cited by this paper
• Telomerase catalytic subunit homologs from fission yeast and human.

  1997cited by this paper
• A survey of telomerase activity in human cancer.

  1997cited by this paper
• Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer.

  1997cited by this paper
• p53 and treatment of bladder cancer

  1997cited by this paper
• Implications of urinary basic fibroblast growth factor excretion in patients with urothelial carcinoma.

  1996cited by this paper
• Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence.

  1996cited by this paper
• Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection.

  1996cited by this paper
• E‐cadherin cell‐adhesion molecule expression as a diagnostic adjunct in urothelial cytology

  1996cited by this paper
• Evaluation of c-ras oncogene product (p21) in superficial bladder cancer.

  1996cited by this paper
• Expression of c‐myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer

  1995cited by this paper
• Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.

  1995cited by this paper
• Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis.

  1995cited by this paper
• E‐cadherin expression in bladder cancer using formalin‐fixed, paraffin‐embedded tissues: Correlation with histopathological grade, tumour stage and survival

  1995cited by this paper
• Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.

  1995cited by this paper
• Deletion of the p16 and p15 genes in human bladder tumors.

  1995cited by this paper
• Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.

  1995cited by this paper
• Accumulation of nuclear p53 and tumor progression in bladder cancer.

  1994cited by this paper
• Altered patterns of MDM2 and TP53 expression in human bladder cancer.

  1994cited by this paper
• Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas.

  1994cited by this paper
• Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.

  1994cited by this paper
• Specific association of human telomerase activity with immortal cells and cancer.

  1994cited by this paper
• Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine.

  1993cited by this paper
• Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression

  1993cited by this paper
• Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients.

  1993cited by this paper
• Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder.

  1993cited by this paper
• Over‐expression of p53 nuclear oncoprotein in transitional‐cell bladder cancer and its prognostic value

  1993cited by this paper
• p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

  1993cited by this paper
• Cancer. p53, guardian of the genome.

  1992cited by this paper
• Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.

  1992cited by this paper
• Markers of prognosis in superficial bladder cancer.

  1992cited by this paper
• p53, guardian of the genome

  1992cited by this paper
• The role of angiogenesis in tumor growth.

  1992cited by this paper
• Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer.

  1992cited by this paper
• The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F.

  1991cited by this paper
• Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder.

  1990cited by this paper
• Detection of the c‐myc Gene Product in Urinary Bladder Cancer

  1990cited by this paper
• HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor.

  1989cited by this paper
• What is the role of angiogenesis in metastasis from cutaneous melanoma?

  1987cited by this paper
• Structural evidence for the authenticity of the human retinoblastoma gene.

  1987cited by this paper
• The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

  1986cited by this paper
• Cytologic spectrum of bladder cancer.

  1984cited by this paper

• Bladder cancer.

  2020cites this paper
• Interplay between CKS2, N-cadherin, and PD-ECGF in Non-Schistosomal and Schistosomal-Associated Bladder Cancer: A Prospective Comparative Study in the Egyptian Population

  2017cites this paper
• Bladder cancer

  2016cites this paper
• Urothelial carcinoma associated with Balkan endemic nephropathy. A worldwide disease.

  2011cites this paper
• Intervention of nicotine on MNU-induced bladder cancer in rats

  2011cites this paper
• Intervention of nicotine on MNU-induced bladder cancer in rats

  2011cites this paper
• Carcinogenetic Pathway of Urothelial Carcinoma

  2010cites this paper
• The Role of Urinary Fibronectin and Telomerase in Patients with Superficial Bladder Cancer after Transurethral Resection Treated with BCG

  2010cites this paper
• Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer*

  2009cites this paper
• Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation.

  2008cites this paper
• Roles of estrogen receptor a and b in modulating urothelial cell proliferation

  2008influential citation
• The clinical significance of autoantibodies in gastrointestinal malignancies: an overview

  2007cites this paper
• Biologic therapies in gastrointestinal cancer: Is there any light at the end of the tunnel?

  2007cites this paper
• A novel magnetic bead‐based assay with high sensitivity and selectivity for analysis of telomerase in exfoliated cells from patients with bladder and colon cancer

  2007cites this paper
• E-cadherin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats.

  2006cites this paper
• C-terminal binding proteins: Emerging roles in cell survival and tumorigenesis

  2006cites this paper
• Additional Gene Therapy with rAAV-wt-p53 Enhanced the Efficacy of Cisplatin in Human Bladder Cancer Cells

  2006cites this paper
• Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up.

  2006cites this paper
• Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up.

  2006cites this paper
• DNA content analysis, expression of Ki-67 and p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and treated with mitomycin C and bacillus Calmette-Guérin.

  2006cites this paper
• New Insights in Telomerase and Telomeric Proteins and Their Clinical Application to Urological Cancers

  2005cites this paper
• Biochemical and molecular markers in renal cell carcinoma: an update and future prospects

  2005cites this paper
• Bladder cancer.

  2002cites this paper
• Bladder cancer

  2000cites this paper